REFERENCES
1. Scheinfeld N. Tigecycline: a review of a new glycylcycline
antibiotic. J Dermatolog Treat. 2005;16(4):207–212. doi:
10.1080/09546630510011810
2. McArthur KE. Review article: drug-induced pancreatitis. Aliment
Pharmacol Ther. 1996;10(1):23–38. doi:
10.1111/j.1365-2036.1996.tb00174.x
3. Bhattacharya M, Parakh A, Narang M. Tigecycline. J Postgrad
Med. 2009;55(1):65–68. doi: 10.4103/0022-3859.48443
4. Occhionorelli S, Morganti L, Cultrera R, et al. Acute necrotizing
pancreatitis: can tigecycline be included in a therapeutic strategy?G Chir . 2015;1(1):15–20.
5. Wang J, Pan Y, Shen J, et al. The efficacy and safety of tigecycline
for the treatment of bloodstream infections: a systematic review and
meta-analysis. Ann Clin Microbiol Antimicrob . 2017;16(1):24. doi:
10.1186/s12941-017-0199-8
6. Lin J, Wang R, Chen J, et al.
Tigecycline-induced acute pancreatitis in a renal transplant patient:
a case report and literature review. BMC Infect Dis.2018;18(1):201. doi: 10.1186/s12879-018-3103-z
7. Chang C, Qiao W, Wang H, et al. Tigecycline-associated acute
pancreatitis in a child with pulmonary cystic fibrosis: a case report
and literature review. Int J Clin Pharmacol Ther.2022;60(1):41–45. doi: 10.5414/CP204073
8. Nitsche CJ, Jamieson N, Lerch MM, et al. Drug induced pancreatitis.Best Pract Res Clin Gastroenterol. 2010;24(2):143–155. doi:
10.1016/j.bpg.2010.02.002
9. Banks PA, Bollen TL, Dervenis C, et al. Classification of acute
pancreatitis – 2012: revision of the Atlanta classification and
definitions by international consensus. Gut. 2013;62(1):102–111.
doi: 10.1136/gutjnl-2012-302779
10. Mortele KJ, Wiesner W, Intriere L, et al. A modified CT severity
index for evaluating acute pancreatitis: improved correlation with
patient outcome. AJR Am J Roentgenol. 2004;183(5):1261–1265.
doi: 10.2214/ajr.183.5.1831261
11. Weissman S, Aziz M, Perumpail RB, et al. Ever-increasing diversity
of drug-induced pancreatitis. World J Gastroenterol.2020;26(22):2902–2915. doi: 10.3748/wjg.v26.i22.2902
12. Hu J, Xiao YH, Zheng Y, et al. Clinical characteristics and risk
factors of tigecycline-associated hypofibrinogenaemia in critically ill
patients. Eur J Clin Pharmacol. 2020;76(7):913–922. doi:
10.1007/s00228-020-02860-w
13. McGovern PC, Wible M, Korth-Bradley JM, et al. Pancreatitis in
tigecycline phase 3 and 4 clinical studies. J Antimicrob
Chemother. 2014;69(3):773–778. doi: 10.1093/jac/dkt427
14. Gilson M, Moachon L, Jeanne L, et al. Acute pancreatitis related to
tigecycline: case report and review of the literature. Scand J
Infect Dis. 2008;40(8):681–683. doi: 10.1080/00365540801938949
15. Fang W, Yi D, Sun L, et al. Analysis of clinical characteristics of
tigecycline-induced acute pancreatitis. J Clin Pharm Ther.2020;45(6):1320–1324. doi: 10.1111/jcpt.13212
16. Okon E, Engell C, van Manen R, et al.
Tigecycline-related pancreatitis: a review of spontaneous adverse event
reports. Pharmacotherapy. 2013;33(1):63–68. doi:
10.1002/phar.1159
17. Zhanel GG, Karlowsky JA, Rubinstein E, et al. Tigecycline: a novel
glycylcycline antibiotic. Expert Rev Anti Infect Ther.2006(1);4:9–25. doi: 10.1586/14787210.4.1.9.
18. Elmore MF, Rogge JD. Tetracycline-induced pancreatitis.Gastroenterology. 1981;81(6):1134–1136.
19. Banks PA, Freeman ML, Practice Parameters Committee of the American
College of Gastroenterology. Practice guidelines in acute pancreatitis.Am J Gastroenterol. 2006;101(10):2379–2400. doi:
10.1111/j.1572-0241.2006.00856.x
20. Mole DJ, Olabi B, Robinson V, et al. Incidence of individual organ
dysfunction in fatal acute pancreatitis: analysis of 1024 death records.HPB (Oxford). 2009;11(2):166–170. doi:
10.1111/j.1477-2574.2009.00038.x
21. Dellinger RP, Carlet JM, Masur H. Surviving Sepsis Campaign
guidelines for management of severe sepsis and septic shock. Crit
Care Med. 2004;32(3):858–873. doi: 10.1097/01.ccm.0000117317.18092.e4